Glaukos (NYSE:GKOS) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Glaukos (NYSE:GKOS) from a hold rating to a buy rating in a research note issued to investors on Saturday.

A number of other research firms have also issued reports on GKOS. HC Wainwright lifted their target price on Glaukos from $168.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday. UBS Group started coverage on shares of Glaukos in a report on Tuesday. They issued a “neutral” rating and a $150.00 price target for the company. Truist Financial raised their price objective on shares of Glaukos from $180.00 to $215.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC raised their price objective on shares of Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a research report on Thursday. Finally, William Blair reaffirmed an “outperform” rating on shares of Glaukos in a research note on Tuesday, May 26th. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $177.33.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $166.52 on Friday. The stock has a fifty day moving average price of $138.11 and a two-hundred day moving average price of $125.07. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.04. The firm has a market cap of $9.82 billion, a P/E ratio of -51.24 and a beta of 0.75. Glaukos has a 1 year low of $73.16 and a 1 year high of $184.00.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company had revenue of $185.61 million for the quarter, compared to analysts’ expectations of $150.93 million. During the same period last year, the firm earned ($0.24) EPS. The firm’s revenue for the quarter was up 49.6% on a year-over-year basis. Research analysts forecast that Glaukos will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In related news, CFO Alex R. Thurman sold 10,000 shares of the stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $160.00, for a total value of $1,600,000.00. Following the completion of the transaction, the chief financial officer owned 43,906 shares in the company, valued at $7,024,960. This trade represents a 18.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the transaction, the director directly owned 35,528 shares in the company, valued at $5,000,921.28. This represents a 12.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 40,000 shares of company stock valued at $6,028,800. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Handelsbanken Fonder AB raised its holdings in shares of Glaukos by 5.9% during the second quarter. Handelsbanken Fonder AB now owns 19,800 shares of the medical instruments supplier’s stock valued at $2,767,000 after acquiring an additional 1,100 shares during the period. Valeo Financial Advisors LLC boosted its stake in Glaukos by 4.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 9,892 shares of the medical instruments supplier’s stock worth $1,383,000 after purchasing an additional 440 shares during the period. Assenagon Asset Management S.A. grew its position in Glaukos by 932.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 108,736 shares of the medical instruments supplier’s stock worth $15,197,000 after purchasing an additional 98,205 shares in the last quarter. GAMMA Investing LLC grew its position in Glaukos by 35.4% during the 2nd quarter. GAMMA Investing LLC now owns 3,165 shares of the medical instruments supplier’s stock worth $442,000 after purchasing an additional 827 shares in the last quarter. Finally, Moody National Bank Trust Division purchased a new position in Glaukos during the 2nd quarter worth approximately $246,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Quarterly results exceeded expectations. Glaukos reported second-quarter revenue of $185.6 million, up 49.6% year over year and well above the $150.9 million consensus estimate. Its adjusted loss of $0.14 per share was narrower than the expected $0.21 loss, supported by growth in iDose TR and Epioxa. Glaukos Q2 Earnings Beat Estimates on iDose TR Growth
• Positive Sentiment: Management raised its 2026 outlook. Glaukos now expects net sales of $680 million to $700 million, with iDose TR revenue projected at $275 million to $280 million. The higher forecast signals continued commercial momentum and was a key reason the stock advanced. Glaukos outlines 2026 sales outlook
• Positive Sentiment: Clinical and analyst catalysts added support. The company reported progress on its PRESERFLO study, while BTIG raised its price target from $164 to $193 and maintained a Buy rating. BTIG raises Glaukos price target
• Neutral Sentiment: UBS Group initiated coverage of Glaukos, potentially broadening institutional attention, although the available report does not provide a detailed rating or price target. UBS initiates Glaukos coverage
• Negative Sentiment: Valuation and profitability remain risks. Despite the improved results, Glaukos remains unprofitable, and commentary questioned whether the stock’s strong rally has priced in much of its growth potential. Future gains may depend on continued iDose TR adoption and execution against the raised forecast. Glaukos record sales and valuation analysis

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.